Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors

被引:59
作者
Aranda, Fernando [1 ]
Llopiz, Diana [1 ]
Diaz-Valdes, Nancy [1 ]
Ignacio Riezu-Boj, Jose [1 ]
Bezunartea, Jaione [1 ]
Ruiz, Marta [1 ]
Martinez, Marta [1 ]
Durantez, Maika [1 ]
Mansilla, Cristina [1 ]
Prieto, Jesus [1 ]
Jose Lasarte, Juan [1 ]
Borras-Cuesta, Francisco [1 ]
Sarobe, Pablo [1 ]
机构
[1] Univ Navarra, Ctr Appl Med Res CIMA, Div Hepatol & Gene Therapy, Pamplona 31008, Spain
关键词
DENDRITIC CELLS; ANTITUMOR IMMUNITY; IN-VITRO; VIRUS; SUPERIOR; RNA; POPULATIONS; ACTIVATION; EXPANSION; CORRELATE;
D O I
10.1158/0008-5472.CAN-10-3259
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Low antigen expression and an absence of coimmunostimulatory signals may be partly responsible for the low immunogenicity of many tumors. It may be possible to overcome this situation by defining a combination of adjuvants and antigens that can activate a high-avidity antitumor response. Using the poorly immunogenic B16-OVA melanoma cells as tumor model, we tested different combinations of adjuvants and antigens to treat established tumors. In the absence of exogenous antigens, repeated administration of the TLR7 ligand Imiquimod together with anti-CD40 agonistic antibodies activated only innate immunity, which was insufficient to reject intradermal tumors. Administering this adjuvant combination together with OVA as a tumor antigen induced T-cell responses that delayed tumor growth. However, administering a combination of anti-CD40 plus TLR3 and TLR7 ligands, together with antigen targeting to dendritic cells through TLR4, was sufficient to induce tumor rejection in 50% of mice. This response was associated with a greater activation of innate immunity and induction of high-avidity polyfunctional CD8(+) T-cell responses, which each contributed to tumor rejection. This therapy activated T-cell responses not only against OVA, which conferred protection against a rechallenge with B16-OVA cells, but also activated T-cell responses against other melanoma-associated antigens. Our findings support the concept that multiple adjuvant combination and antigen targeting may be a useful immunotherapeutic strategy against poorly immunogenic tumors. Cancer Res; 71(9); 3214-24. (C) 2011 AACR.
引用
收藏
页码:3214 / 3224
页数:11
相关论文
共 39 条
  • [1] Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN
    Ahonen, CL
    Doxsee, CL
    McGurran, SM
    Riter, TR
    Wade, WF
    Barth, RJ
    Vasilakos, JP
    Noelle, RJ
    Kedl, RM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (06) : 775 - 784
  • [2] Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
    AlexanderMiller, MA
    Leggatt, GR
    Berzofsky, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) : 4102 - 4107
  • [3] Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
    Alexopoulou, L
    Holt, AC
    Medzhitov, R
    Flavell, RA
    [J]. NATURE, 2001, 413 (6857) : 732 - 738
  • [4] Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
    Ashley, DM
    Faiola, B
    Nair, S
    Hale, LP
    Bigner, DD
    Gilboa, E
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) : 1177 - 1182
  • [5] Dendritic cells and the control of immunity
    Banchereau, J
    Steinman, RM
    [J]. NATURE, 1998, 392 (6673) : 245 - 252
  • [6] Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
    Bellone, M
    Cantarella, D
    Castiglioni, P
    Crosti, MC
    Ronchetti, A
    Moro, M
    Garancini, MP
    Casorati, G
    Dellabona, P
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (05) : 2651 - 2656
  • [7] HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    Betts, Michael R.
    Nason, Martha C.
    West, Sadie M.
    De Rosa, Stephen C.
    Migueles, Stephen A.
    Abraham, Jonathan
    Lederman, Michael M.
    Benito, Jose M.
    Goepfert, Paul A.
    Connors, Mark
    Roederer, Mario
    Koup, Richard A.
    [J]. BLOOD, 2006, 107 (12) : 4781 - 4789
  • [8] Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
    Boczkowski, D
    Nair, SK
    Snyder, D
    Gilboa, E
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) : 465 - 472
  • [9] Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma
    Brinkman, M
    Walter, J
    Grein, S
    Thies, MJW
    Schulz, TW
    Herrmann, M
    Reiser, COA
    Hess, J
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (06) : 611 - 622
  • [10] Tumours can act as adjuvants for humoral immunity
    Brown, DM
    Fisher, TL
    Wei, C
    Frelinger, JG
    Lord, EM
    [J]. IMMUNOLOGY, 2001, 102 (04) : 486 - 497